Some studies suggest that high-estrogen levels lead to erectile dysfunction (ED); high-estrogen levels are known to decrease testosterone levels. However, no study has examined whether testosterone replacement can improve the ED induced by highestrogen levels. We investigated the effects of testosterone on ED caused by high-estrogen levels in rats. Rats were distributed in the following groups: (1) control (vehicle for 2 weeks), (2) the estrogen-treated group (ES; estradiol (3 mg kg À 1 day À 1 ) for 2 weeks), and (3) the estrogen-and testosterone-treated group (ES þ TE; estradiol (3 mg kg À 1 day À 1 ) and testosterone (3 mg kg À 1 day
INTRODUCTION
Erectile function has a complex underlying mechanism affected by several factors. [1] [2] [3] [4] Some recent studies have suggested that one of these factors may be estrogen levels. [5] [6] [7] [8] [9] [10] [11] [12] For example, Baser et al. 5 suggested that serum estrogen levels are correlated with symptoms of aging in men, and estrogen may therefore have an important role in these symptoms. Greco et al. 6 reported that tadalafil treatment suppressed estrogen levels in some obese men and improved their erectile function domain scores. Further, Srilatha et al. 7, 8 reported high-estrogen levels in elderly patients with erectile dysfunction (ED) sexual disinterest and therefore suggested that a pathophysiological estrogen-testosterone imbalance is involved in these conditions among the elderly.
In a basic study, Goyal et al. reported that estrogen caused developmental disorders of the rat penis and that it decreased penile testosterone levels. 9 , 10 Adaikan and Srilatha 11 reported that estrogen caused pathophysiological changes in the corpus cavernosum and a decline in erectile function in rats. They also reported that estrogen induction enhanced corpus cavernosum smooth muscle contraction and decreased smooth muscle relaxation in rabbits. 12 Collectively, these previous results suggest that high-estrogen levels decrease erectile function. 11, 12 However, high-estrogen levels also decrease testosterone levels. Therefore, it is not yet clear whether it is the changes in estrogen or changes in testosterone that cause ED.
To clarify the exact role played by estrogen in erectile function, we investigated erectile function in rats in a high-estrogen milieu and determined the effect of testosterone in this milieu. We aimed to ascertain whether restoration of testosterone levels can improve the ED caused by high-estrogen levels.
MATERIALS AND METHODS Animals
Thirteen-week-old male Wistar ST rats (220-270 g; Japan SLC, Hamamatsu, Japan) were used in all the study protocols. The experimental protocol was approved by the Ethics Review Board of Nagoya City University, and the study was conducted in accordance with Nagoya City University's standards for the care and use of animals.
Animal groups and treatment protocol
The rats were grouped according to the changes that were experimentally induced in their sex hormone milieu, as described in Figure 1 . Rats in the estrogen-treated group (ES; n ¼ 11) were administered estradiol (3 mg kg À 1 day À 1 subcutaneously) dissolved in saline containing 1% Tween for 2 weeks. In the estrogen-and testosterone-treated group (ES þ TE; n ¼ 11), rats were injected with estradiol and testosterone (3 mg kg À 1 day À 1 subcutaneously) for 2 weeks. Finally, the rats in the control group (control; n ¼ 11) were injected with the vehicle alone for 2 weeks. For all the groups, injections were administered between 1300 and 1700 hours. Erectile function was measured at the end of the 2-week treatment period.
Evaluation of erectile function
The intracavernous pressure (ICP) elicited by electrical stimulation was measured according to a previously described method. 13, 14 In brief, rats from each group were anesthetized using an intraperitoneal injection of pentobarbital sodium (50 mg kg À 1 ). For continuous monitoring of mean arterial pressure (MAP), the left side of the neck was incised and the carotid artery was cannulated to connect using a pressure transducer with polyethylene (PE)-50 tubing anticoagulated with 50 U l À 1 of heparin. The pressure transducer was connected through a transducer amplifier to a data acquisition board (PowerLab 2/26; AD Instruments, Pty., Bella Vista, New South Wales, Australia). For continuous ICP monitoring, the left crus of 1 the corpus cavernosum was cannulated with a 23-G needle and connected to a pressure transducer through PE-50 tubing anticoagulated with 50 U l À 1 heparin. To initiate penile erection, both sides of the separated cavernous nerve were stimulated with bipolar stainless steel wire electrodes (Unique Medical Osaka, Japan) and a pulse generator (Nihon Kohden Tokyo, Japan). The maximum ICP and MAP of the rats were subsequently measured. The stimulation parameters were as follows: 10 V, 20 Hz, a square-wave duration of 5 ms, a duration of 1 min. Response parameters were calculated using the Chart and Scope software (AD Instruments).
Erectile function was evaluated on the basis of the maximum ICP/MAP ratios, as ICP is influenced by systemic arterial pressure.
Measurement of sex hormones
After erectile function was measured, the bioavailable testosterone (bio-T) and estrogen (estrone and estradiol) levels were measured in blood samples obtained from the vena cava of each rat between 1300 and 1700 hours. The samples were coagulated and centrifuged at 800 g for 20 min at 4 1C. Serum samples were stored at À 80 1C until analysis.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to measure serum sex hormone levels. Dexamethasone was used as the internal standard working solution. Concanavalin A was added to the serum samples to remove sex hormone-binding globulin. 15 To improve their detectability, estrone, estradiol, testosterone and dexamethasone were derivatized, for which a reagent mixture (50 mg of 2-methyl-6-nitrobenzoic anhydride, 10 mg of 4-dimethylaminopyridine and 30 mg of picolinic acid in 1 ml of tetrahydrofuran) and 10 ml of triethylamine were added to the tubes. 16 After derivatization, the resulting solutions were passed through Oasis HLB cartridges (30 mg, C 18 ; Waters Corporation, Milford, MA, USA) for removal of serum proteins. Samples thus prepared were subjected to LC-MS/MS.
The LC-MS/MS conditions for sex hormone measurement were as follows. The LC system consisted of a 2777 c sample manager (Waters Corporation) coupled with a 1525 m binary HPLC pump (Waters Corporation). An Inertsil ODS-3 column (2.1 Â 50 mm 2 ; GL Sciences, Tokyo, Japan) was used for chromatographic separation in water:acetonitrile (40:60, v/v) with 0.1% acetic acid as the mobile phase. The multiple reaction-monitoring transitions, which measure mass-to-charge ratio (m/z; parent ion-daughter ion), were m/z 376.24-77.9 for the estrone derivative, m/z 483.14-78.14 for the estradiol derivative, m/z 394.30-124.09 for the testosterone derivative and m/z 498.35-123.8 for the dexamethasone derivative. Chromatographic data were processed using the Mass Lynx software (Waters Corporation).
Evaluation of smooth muscle function on the basis of isometric tension
For evaluation of smooth muscle function, the rat penes were removed, and the glans, urethra, blood vessels and tunica albugirea were excised from the penes. Strips of the corpus cavernosum were prepared and rinsed in cold Krebs solution (in mM: NaCl, 119; KCl, 4.6; CaCl 2 , 1.5; MgCl 2 , 1.2; NaHCO 3 , 15; D-glucose, 11; and NaH 2 PO 4 , 1.2). The strips were equilibrated for at least 60 min in an organ bath containing Krebs solution and aerated with 95% O 2 and 5% CO 2 at 37 1C. The tissue resting force was set to 500 mg. Changes in isometric tension were recorded using a force transducer (Nihon Kohden) connected to a data acquisition board (PowerLab 2/26; AD Instruments). The contractile capacity of the strips was tested by exposure to 80 mM of high-potassium solution (in mM: NaCl, 36.7; KCl, 80; CaCl 2 , 2.2; MgCl 2 , 1.2; NaHCO 3 , 25; D-glucose, 14; and KH 2 PO 4 , 1.2). Relaxant experiments were conducted using strips precontracted with 10 mM of noradrenaline (NA; Sigma Aldrich, MO, USA). The relaxant effect was induced using the RhoA/Rho-kinase inhibitor Y-27632 (Wako Pure Chemical Industries, Osaka, Japan) and sodium nitroprusside (SNP; Sigma Aldrich). Stock solutions of all reagents were stored at À 20 1C until use. Cumulative dose (10 À 10 -10 À 4 M) response curves for SNP, NA and Y-27632 were created using different tissue sets. Response parameters were calculated using the Chart and Scope software (AD Instruments).
Statistical analysis
Results are expressed as the mean±s.e.m. Statistical significance was determined by a one-or two-way analysis of variance and a Bonferronitype multiple t-test. The level of significance was set at Po0.05. The halfmaximal response inhibitory concentration (IC 50 ) value was calculated using the IC 50 for graded response programs. Table 1 , the estrogen level was significantly higher (F ¼ 24.2, Po0.01), whereas the bio-T level was significantly lower (F ¼ 19.0, Po0.05) in the ES group than in the control group. In the ES þ TE group, the bio-T level was significantly higher than (F ¼ 19.0, Po0.01) and the estrogen level was not significantly different from that in the ES group.
RESULTS

Serum levels of sex hormones As indicated in
Smooth muscle function
The relaxant responses of NA-precontracted rat corpus cavernosum strips to increasing concentrations of the Rho-kinase inhibitor Y-27632 are shown in Figure 2 . Y-27632 completely relaxed the rat corpus cavernosum strips in all the groups. The graphs for the ES and ES þ TE groups are left-shifted, indicating that the sensitivities to Y-27632 in the ES and ES þ TE groups were significantly higher than that in the control group (control: IC 50 ¼ 1. F¼ 38.0, Po0.01). However, the sensitivity in the ES þ TE group was not significantly different from that in the ES group. Figure 3 shows the contractile response of the rat corpus cavernosum strips to increasing concentrations of NA. NA was found to contract the corpus cavernosum strips in all the groups. The maximum contractile responses in the ES and ES þ TE groups were higher than that in the control group (F ¼ 14.3, Po0.05).
The results of the relaxant response of the corpus cavernosum strips to increasing concentrations of SNP are shown in Figure 4 . The responses to SNP in the ES and ES þ TE groups were significantly lower than that in the control group (F ¼ 11.5, Po0.01). The responses in the ES þ TE group were similar to those in the ES group. Figure 5a shows representative tracings of ICP and arterial pressure changes during electrical stimulation of the cavernous nerve in the rats. The ICP in the ES and ES þ TE groups appeared to be lower than that in the control group. Testosterone treatment did not affect ICP in the ES þ TE group. Figure 5b shows the maximum ICP changes on electrical field stimulation of the cavernous nerve in the different experimental groups. The ICP values in the ES (55.6±2.7 cm H 2 O) and ES þ TE (54.4±3.2 cm Figure 1 . Experimental design. In the control group, rats were injected vehicle for 2 weeks. In the estrogen-treated (ES) group, rats were injected with estradiol (3 mg kg À 1 day À 1 subcutaneously) for 2 weeks. In the estrogen-and testosterone-treated (ES þ TE) group, rats were injected with estradiol (3 mg kg À 1 day À 1 subcutaneously) and testosterone (3 mg kg À 1 day À 1 subcutaneously) for 2 weeks. At the end of the period, rats were underwent erectile function testing in vivo or in vitro. Figure 5c ). Figure 5d shows the results of erectile response assessment in terms of the ICP/MAP ratio. The ratios in the ES (0.43 ± 0.03) and ES þ TE (0.43 ± 0.02) groups were significantly lower than that in the control group (0.73 ± 0.04; F ¼ 32.0, Po0.01). Further, the ICP/MAP ratio in the ES þ TE group was not significantly higher than that in the ES group.
Erectile function
DISCUSSION
We investigated whether a high-estrogen milieu in rats caused ED and whether testosterone supplementation in this high-estrogen milieu affected erectile function. The aim of this study was to determine whether high-estrogen levels affect ED directly or through their testosterone-lowering effects, which have been reported previously.
11,12
The estradiol concentration of 3 mg kg À 1 day À 1 was considered an adequately high dose, and 2 weeks of daily injections were considered appropriate to create a high-estrogen milieu. This protocol is based on the estradiol concentrations and timeline considered appropriate for hormone replacement therapy in ovariectomized rats. 17 The testosterone dose and administration period used in this study were based on the results of a preliminary study wherein rats were castrated and injected with 3 mg kg À 1 day À 1 testosterone for 2 weeks. The resulting ICP/MAP ratios were confirmed to have recovered to the same extent as that in sham-operated rats (data not shown).
The results of this study indicated that although the testosterone levels of the high-estrogen rats increased with testosterone Androgen replacement therapy for ED induced by high estrogen T Kataoka et al treatment, the treatment did not affect the erectile function of these rats.
We determined smooth muscle contractility using an isometric tension study in order to ascertain how ICP/MAP ratios decrease in response to a high-estrogen milieu irrespective of testosterone treatment. We focused on the RhoA/Rho-kinase signaling pathway, a pathway of contractile systems, and reported its relevance to ED. 18 At high-estrogen levels, enhanced sensitivity to the Rhokinase inhibitor, Y-27632, was observed. Other studies have reported enhanced sensitivity to Rho-kinase inhibitors, in association with increased expression of the Rho-kinase protein.
These studies showed that Rho-kinase activity was higher in animals with enhanced sensitivity to Y-27632 than in control animals.
19-21 Although we did not examine the expression of the Rho-kinase protein, we demonstrated that Rho-kinase activity was enhanced in a high-estrogen milieu.
Our results showed that when the RhoA/Rho-kinase signaling pathway was upregulated, NA-induced contraction increased in rats with high levels of estrogen. Further, the relaxation induced by SNP was relatively lower in rats with high levels of estrogen than in control rats. The RhoA/Rho-kinase signaling pathway has important roles in smooth muscle contraction and the nitric oxide (NO)-mediated relaxation system. 22, 23 Some studies have reported the relationship between the Rho/Rho-kinase signaling pathway and NO/cyclic guanosine monophosphate signaling pathway. [24] [25] [26] For example, Saito et al. 26 reported that inhibition of Rho-kinase ameliorated NO-mediated relaxation in the corpus cavernosum smooth muscle of spontaneously hypertensive rats. Our findings suggest that a high-estrogen milieu may enhance smooth muscle contraction through RhoA/Rho-kinase upregulation, and this enhanced contraction would interfere with smooth muscle NOmediated relaxation. This phenomenon would, in turn, lead to a decrease in the ICP/MAP ratio and extensive loss of corpus cavernosum function.
Our findings suggest that testosterone treatment did not improve ED in rats injected with estrogen. Estrogen is produced from testosterone by aromatase, an enzyme abundant in visceral adipose tissue, 27 which may explain the elevated estradiol levels among obese men. 28 In men, visceral adipose tissue often accumulates with increasing age. 29 Therefore, older and obese men have a high incidence of ED. [30] [31] [32] [33] On the other hand, epidemiological studies have suggested that aging and metabolic syndrome are associated with androgen deficiency, [34] [35] [36] [37] [38] and patients with androgen deficiency are usually diagnosed with late-onset hypogonadism and treated with testosterone. However, some studies have suggested that these treatments are not always effective. 39, 40 It is possible that high-estrogen levels lead to low effects of testosterone treatment in elderly patients or those with metabolic syndrome. Moreover, because testosterone is metabolized to estrogen, high-testosterone levels would lead to high-estrogen levels, which may lead to ED. 27 In conclusion, we found that a high-estrogen milieu affected erectile function in rats, and testosterone treatment did not improve erectile function under these conditions. These findings were supported by both in vivo and in vitro experiments and suggest that high levels of estrogen cause ED by enhancing Rhokinase-mediated smooth muscle contraction. Therefore, a highestrogen level should be considered a risk factor for ED. Exercise or lifestyle modifications may reduce visceral adipose tissue and thus suppress estrogen levels, which may improve endocrine ED.
